PCN48 Changes In Glucose Lowering Drug Use Before And After A Cancer Diagnosis Among Individuals With Diabetes  by Zanders, MM et al.
A438  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
is associated with a significant symptom burden. Pruritus appears to be one of 
the most prominent and disturbing symptoms. All aspects of QOL are affected in 
CTCL. Two new treatments were approved for CTCL during 2009-2012 (US), however, 
the unmet need remains high. ConClusions: This systematic review shows that 
patients with CTCL have a very poor prognosis and serious deterioration in quality 
of life. There is an urgent need for new treatments for these patients.
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objeCtives: In France, cancer incidence and mortality rates are readily avail-
able. However, less well known is the number of patients with an active disease. 
Existing prevalence data, often coming from probabilistic models, aggregate both 
cured patients having received curative treatments at an early stage and patients 
with a metastatic disease. Since the latter represent the essentials of current 
treatment needs, their recognition is necessary to evaluate crucial treatment 
resources. Methods: Conducted in France every 2 years, the ‘Cancérologie’ study 
includes an observational component requiring participating physicians to report on 
the current status and treatment of their next 15 patients (12 until 2009) seen with 
any solid or liquid cancer in the active phase. Thus, 4,430 patients were reported 
during the 2013 study (as opposed to 2,260 in 2003). Data collected were extrapo-
lated to the whole of France, using activity data from hospitals as projection coef-
ficients. Results: Between 2003 and 2013, the total number of patients treated 
for an active disease in French healthcare facilities rose from 394,000 to 521,000, 
showing an average annual increase of 2.8% which is above the estimated annual 
increase in incidence over the same period (1.7%). Meanwhile, among all patients, 
the distribution of solid tumors versus liquid tumors has remained almost identi-
cal (ratio between 90/10 and 88/12). However, the number of patients treated for a 
metastatic tumor has risen by 71% from 157,000 patients in 2003 to 269,000 in 2013 
(from 39% to 60% of total patients). Prostate, colorectal and breast cancers have been 
the strongest contributors (40%) to this increase. ConClusions: The 71% increase 
in the number of patients treated for a metastatic disease is undoubtedly the most 
significant occurrence of these past ten years in oncology. The monitoring of this 
trend, overall and by indication, is a priority.
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objeCtives: The incidence of malignant melanoma has increased in the recent 
years and the role of ultraviolet radiation (UV) in the disease process is well estab-
lished. Indeed, epidemiological data supported that sun exposure and, more par-
ticularly sunburns during childhood are associated with a higher risk of developing 
melanoma. The present study aims at evaluating the prevalence of skin cancer and 
other skin disorders in the Mexican population and at determining the risk factors 
associated with these conditions Methods: A total of 400 dermatologists practic-
ing in the 11 most important cities of Mexico have been selected to participate in 
the study. Over a period of one week, each year from 2011 to 2014, they submitted 
questionnaires to every consulting patient. These questionnaires comprised two 
sections: one completed by the patient to gather data on risk factors and the other 
by the dermatologist to collect medical history and current diagnosis. Results: A 
total of 11841 questionnaires were completed. The mean age of the study popula-
tion was 49.3 years and respondents were predominantly women (sex ratio 2:1). The 
phototype III is the most frequently reported by study participants (about 36%) how-
ever, phototype II and IV are also cited each, by approximately 20% of individuals. 
Most study participants did not report any severe sunburns during childhood and 
almost 40% of them spent more than one hour a day in the sun. Very few patients 
have personal or family history of melanoma and less than 15% have suffered from 
non-melanoma skin cancer. At the time of the clinical examination, melanoma was 
rarely suspected (about 2% of cases). The most frequent disorder appeared to be 
basal cell carcinoma with 7% of individuals potentially affected ConClusions: 
Results from this observational study confirmed variations in the prevalence of 
the various types of skin cancer.
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objeCtives: We assessed the patient characteristics and burden of cancer hospi-
talizations amongst the most prevalent cancers in the United States. Methods: 
We conducted a cross-sectional study of the 2012 National Inpatient Sample. 
Utilizing ICD-9 codes, we identified cancers with the highest mortality rates in 
males and females. Frequencies and proportions for patient and hospital char-
acteristics were compared using bivariate statistics. Multivariable analyses were 
used to assess the outcomes associated with cancer hospitalizations while 
adjusting for confounding, including a generalized linear model for charges and 
a negative binomial model for differences in length of stay (LOS). Results: We 
estimated the incidence of cancer hospitalizations at 471,755 cases. Lung cancers 
accounted for the greatest proportion of cancer hospitalizations (27.46%), while 
liver cancers accounted for the lowest proportion (4.43%). Colorectal (median: 6 
days [Interquartile Range (IQR): 4-10]) and pancreatic (median: 6 days [IQR: 3-10]) 
cancers were associated with the longest LOS. The overall median charges for hos-
pitalization was also highest for colorectal cancer ($50,761 [IQR: $31,352-83,233]); 
however, the median charges per day were highest for prostate cancer ($23,589 
about 1.7-times more than at 3 months before death. ConClusions: If pain of can-
cer patients can be appropriately controlled according to the guideline, unnecessary 
hospitalization and ER visits will be reduced, resulting in improved quality of life of 
patients and efficient use of medical expenses; however, a number of obstacles exist 
for cancer pain control in real practice.
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objeCtives: This study explores changes in glucose lowering drug (GLD) use 
associated with cancer development and treatment among diabetic individu-
als. Methods: New GLDs users (1998-2011) living in the ECR-PHARMO catchment 
area were selected (n= 52,228). Those with a primary cancer diagnosis were con-
sidered cases (n= 3,281) and matched with eligible controls without cancer during 
follow-up (n= 12,891). Conditional logistic regression analysis was used to assess 
changes in GLD use, i.e. treatment drop and initiating insulin, for cases compared 
to controls due to specific cancer types in four time windows (3-6 and 0-3 months 
before cancer diagnosis; 0-3 and 3-6 months after cancer diagnosis). Results: 
In the 3-6 months before cancer diagnosis, gastrointestinal and pancreas cancer 
were associated with higher odds of starting with insulin (OR 3.9;95%CI 1.3-12.1 
and OR 4.9;95%CI 1.3-18.1). Colorectal (OR 3.4; 95%CI 1.4-8.4) and gastrointestinal 
(OR 13.6;95%CI 5.0-36.9) cancers were associated with increased odds of initiating 
insulin in the 3 months after cancer diagnosis. After this period, these odds were 
increased for breast (OR 4.6;95%CI 1.7-12.6) and pulmonary (OR 3.3;95%CI 1.2-9.1) 
cancers. Within all time windows odds of treatment drops were higher for patients 
with gastrointestinal cancers, while for all other cancers (except breast and pros-
tate) odds were only higher after cancer diagnosis. ConClusions: Already 3 to 6 
months before the diagnosis of gastrointestinal or pancreas cancer a higher odds 
of initiating insulin use was observed, suggesting reverse causation. Stopping GLDs 
was common after cancer diagnosis, while the diagnosis of most cancer types was 
associated with the start of insulin.
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objeCtives: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) 
has been increasing in many countries worldwide, predominantly among men in 
developed countries. OPSCC is strongly associated with human papilloma virus 
(HPV) infection, and HPV-related OPSCC has been described as an emerging epi-
demic. As HPV-related cervical cancer has been decreasing in many countries, it 
has been predicted that the number of cases of OPSCC will soon overtake cervical 
cancer. Methods: We used an administrative claims database to identify occur-
rences of diagnosis codes for cervical cancer versus diagnosis codes for cancer of 
sites known to comprise HPV-related OPSCC (oropharynx, tonsil, lingual tonsil, 
uvula, soft palate, and base of tongue)among males in the years 2005-2014. We 
calculated ratios of identified diagnoses in each calendar year. Differences in 
healthcare costs between males with OPSCC and females with cervical cancer in 
the 12 months after first diagnosis in 2013 for patients with ≥ 6 months of con-
tinuous enrollment were estimated. Results: Males comprised 73% of all OPSCC 
diagnoses in 2005 and 79% in 2014. The ratio of cervical cancer diagnoses versus 
OPSCC was 1.61 in 2005, with an inversion to 0.98 by 2014. Ratios decreased steadily 
from 2005 to 2014. A total of 3,286 OPSCC diagnoses in 2005 and 7,694 diagnoses in 
2014 were identified among males, with 5,290 and 7,572 for cervical cancer, respec-
tively. For males with OPSCC, overall costs in the year after first 2013 diagnosis 
was $56,974 for patients aged 50-54 and $58,900 for patients aged 55-59. Females 
with cervical cancer averaged $42,987 and $46,513, respectively. ConClusions: 
Trends toward higher relative prevalence of HPV-related OPSCC versus HPV-related 
cervical cancer were confirmed in this population of US patients with employer-
sponsored insurance. The rising incidence and substantial costs associated with 
OPSCC warrant greater attention to prevention efforts through vaccination against 
HPV, particularly among men.
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objeCtives: Cutaneous T-Cell Lymphoma (CTCL) is a rare and serious cancer with 
significant deterioration in patient quality of life. The objective of this research was 
to conduct a systematic review of epidemiology and the burden of CTCL. Methods: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key findings. 
Extracted study data included: CTCL incidence, complications, mortality, available 
treatment options, as well as healthcare resource utilization and medical costs 
associated with CTCL. Critical analyses of study quality and data gaps were analyzed 
at the country level. Results: A total of 50 studies were identified based on the 
keywords. Of these, 14 studies met the inclusion criteria. Studies indicate that CTCL 
is a group of disorders characterized by localization of neoplastic T lymphocytes 
to the skin. Annual overall incidence of CTCL was 6.4 per million persons between 
1973 and 2002. CTCLs accounted for 71%, with Mycosis fungoides (MF) and Sézary 
syndrome (SS) representing the most common sub-types (54 % of all CTCLs). CTCL 
